Two Clinical Studies with IBI301, a Biosimilar Candidate to Rituximab, Met Primary Endpoints
SUZHOU, China, May 8, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and Eli Lilly and Company ("Lilly") jointly announced today that IBI301, a recombinant human-mouse chimeric anti-cell surface protein (anti-CD20) monoclonal antibody being co-developed as a potential bios...
2019-05-08 08:00
9597